title: [Clinical analysis of 165 extremely low birth weight infants].
abstract: OBJECTIVE
  To analyze the clinical features and prognosis of extremely low birth weight infants (ELBWI).
  
  
  METHODS
  Data of totally 165 hospitalized ELBWI between August 1st, 2008 and November 30th, 2013 in Hunan Children's Hospital were analyzed. The information of general data and births, prenatal care, delivery room stabilization, transfer information, complications, treatment, outcome and follow up were summarized.
  
  
  RESULTS
  (1) One hundred and sixty-five ELBWI were involved, their mean gestational age was (28.4±2.4) weeks, mean birth weight(910.9±93.1) g. (2) Rate of delivery in tertiary hospital was 46.7% (77/165) and prenatal steroids exposure was found in 52.1% (86/165). None of the cases were treated with continuous positive airway pressure (CPAP) in delivery room. (3) Rate of infants who were transfered to the class III b neonatal ward within 12 hours after birth was 58.8% (97/165). (4) The main complications of them included neonatal respiratory distress syndrome(NRDS, 77.0%, 127/165), bronchopulmonary dysplasia (BPD, 70.1%, 75/107), patent ductus arteriosus (PDA, 50.0%, 40/80), preterm retinopathy (ROP, 43.0%, 46/107), sepsis 39.4% (65/165), intraventricular hemorrhage (IVH, 34.8%, 49/141), necrotizing enterocolitis (NEC, 8.0%, 7/88). (5) TREATMENT: 97.6% (161/165) received oxygen therapy and 66.1% (109/165) received mechanical ventilation, 55.2% (91/165) used CPAP. 89.8% (114/127) of the NRDS used PS; 44.0% (33/75) of the BPD used low dose dexamethasone, 32.0% (24/75) used low dose nitric oxide; 60.0% (24/40) of the PDA used medication. 32.6% (15/46) of the ROP received laser photocoagulation. The average time of beginning enteral feeding was 2.0 d, the mean time to achieve full gastrointestinal feeding was 43.4 d. (6) OUTCOME: rate of survival in 165 cases with ELBWI was 51.5% (85/165), treatment was abandoned in 37.6% (62/165), total mortality was 48.5% (80/165). There were significant difference in survival rate between different birth weight group, gestational age group and admission age group (χ2=11.498, 8.789, 13.157, all P<0.05); There was significant difference in rate of giving up treatment between different birth weight and admission age groups (χ2=10.448, 8.259, all P<0.05). The primary cause of death was economic factor and worrying about prognosis. (7) Follow up: rate of neurodevelopmental impairment (NDI) in part of follow up cases was 27.9% (12/43).
  
  
  CONCLUSIONS
  ELBWI have many severe complications and sequelae, which need complex treatment and long hospital stay with a low survival rate. In order to improve the level of treatment, we need to improve the rate of prenatal steroids, carry out intrauterine and postnatal, transport of ELBWI to III b neonatal ward as early and rationally as possible, give professional, sophisticated and integrated treatment technologies as far as possible.
authors.affiliation: Department of Neonatology, Hunan Children's Hospital, Changsha 410007, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Zhuang
authors.affiliation: Department of Neonatology, Hunan Children's Hospital, Changsha 410007, China. Email:gaoxirong@126.com.
authors.forename: Xirong
authors.initials: X
authors.lastname: Gao
authors.affiliation: Department of Neonatology, Hunan Children's Hospital, Changsha 410007, China.
authors.forename: Xinhui
authors.initials: X
authors.lastname: Liu
authors.affiliation: Department of Neonatology, Hunan Children's Hospital, Changsha 410007, China.
authors.forename: Yuee
authors.initials: Y
authors.lastname: Xiong
authors.affiliation: Department of Neonatology, Hunan Children's Hospital, Changsha 410007, China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Liu
authors.affiliation: Department of Neonatology, Hunan Children's Hospital, Changsha 410007, China.
authors.forename: Qiong
authors.initials: Q
authors.lastname: Zhang
mesh_terms: D001724:Birth Weight; D001997:Bronchopulmonary Dysplasia / Q000175:diagnosis / Q000628:therapy; D002543:Cerebral Hemorrhage / Q000175:diagnosis / Q000628:therapy; D002681:China / Q000453:epidemiology; D003907:Dexamethasone / Q000627:therapeutic use; D004374:Ductus Arteriosus, Patent / Q000175:diagnosis / Q000628:therapy; D020345:Enterocolitis, Necrotizing / Q000175:diagnosis / Q000628:therapy; D005865:Gestational Age; D006801:Humans; D052577:Infant, Extremely Low Birth Weight; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000175:diagnosis* / Q000628:therapy*; D011379:Prognosis; D012127:Respiratory Distress Syndrome, Newborn / Q000175:diagnosis / Q000628:therapy; D012178:Retinopathy of Prematurity / Q000175:diagnosis / Q000628:therapy; D018805:Sepsis / Q000175:diagnosis / Q000628:therapy; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D003907:Dexamethasone